TGFB1 and Hepatic fibrosis: In vivo, we observed that oral administration of XSSJS in rats with HF (once a day for 12 weeks) could promote the expression of miR-29b-3p and inhibit the expression of VEGFA, PDGF, and TGF-β in rats with liver fibrosis (Figure 7A–H).